Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 229,931 restricted stock units and 206,167 stock options to newly hired employees, approved by its Compensation Committee under the 2018 Inducement Plan. The grants, dated May 3, 2021, aim to attract talent essential for advancing Atara's allogeneic EBV T-cell platform targeting serious diseases. Restricted stock units vest over four years, while stock options have a ten-year term with an exercise price of $14.05 per share. This decision complies with Nasdaq Listing Rule 5635(c)(4).

Positive

• Granting stock options and restricted stock units indicates Atara's commitment to attracting talent necessary for business growth.
• Stock options have a ten-year term, providing long-term incentives for employees.

Negative

• None.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock to 47 newly hired employees and stock options to purchase an aggregate of 206,167 shares of Atara’s common stock to 15 such newly hired employees. These awards were approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of May 3, 2021, as an inducement material to the new employees entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the grant date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates. The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel^® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005457/en/

FAQ

What are the details of the stock grants announced by Atara Biotherapeutics on May 3, 2021?

Atara Biotherapeutics announced the grant of 229,931 restricted stock units and 206,167 stock options to newly hired employees, effective May 3, 2021.

What is the vesting schedule for the stock options granted by Atara Biotherapeutics?

The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.

What is the exercise price of the stock options granted by Atara Biotherapeutics?

The stock options have an exercise price of $14.05 per share, equal to the closing price on May 3, 2021.

How does Atara Biotherapeutics comply with Nasdaq Listing Rule 5635(c)(4)?

Atara is providing this information about stock grants in compliance with Nasdaq Listing Rule 5635(c)(4), which requires disclosure of stock grants to attract employees.